Caroline Germa

5.4k citations

54 papers · 1.1k indexed · h-index 16

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Oncology 39
- Cancer Treatment and Pharmacology 16
- HER2/EGFR in Cancer Research 16
- Colorectal Cancer Treatments and Studies 7
- Lung Cancer Research Studies 5
Pulmonary and Respiratory Medicine 38
- Advanced Breast Cancer Therapies 29

Co-authors: Samit Hirawat Patrick Urban Cristian Massacesi Miguel Martín Emmanuelle di Tomaso Ranjana Tavorath Kongming Wang Nathalie Fretault
Journals: Journal of Clinical Oncology (16 papers)Cancer Research (16 papers)Annals of Oncology (9 papers)European Journal of Cancer (4 papers)Lung Cancer (2 papers)
Partner nations: United States France Spain

In The Last Decade

Caroline Germa

53 papers receiving 1.1k citations

Peers

Countries citing papers authored by Caroline Germa

Since Specialization

Citations

This map shows the geographic impact of Caroline Germa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Germa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Germa more than expected).

Fields of papers citing papers by Caroline Germa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Germa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Germa. The network helps show where Caroline Germa may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Caroline Germa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Caroline Germa Line = papers co-authored together Caroline Germa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 2535: Development of Claudin 18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-claudin 18.2 monoclonal antibody osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinoma Cancer Research ·K. Erdmann, Abner Polzella, Sandra Garber, Baerg MacDonald, James Martin Tinnin, Р Р Сафиуллин, I. -S. Cho, Adil ÖKSÜZ, Xueming Qian, Hanne Øien Halsan, Caroline Germa, Emin Oroudjev	2024	1
2	1524P First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C Annals of Oncology ·Lin Shen, Toshio Kumakiri, Ningning Li, Weijian Guo, Tianshu Liu, Li Zhang, Xia Zhu, Chong Qi, Li Xu, Xiaoping Qian, Caroline Germa	2023	3
3	A View on Drug Development for Cancer Prevention Cancer Discovery ·Andrew R. Reynolds, Michele Moschetta, Fernando Aburto, Farzana L. Walcott, Marianne Ashford, Zoltán Szűcs, 俊誠林, James Hadfield, Zaman Mohammad Shawkat, Benjamin Challis, Larissa Morgana Ferreira Scopel, Gaia Schiavon, Caroline Germa, Shang Yu, G Guimaraes Frederico, Susan Galbraith	2023	11
4	A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors. Journal of Clinical Oncology ·Anthony W. Tolcher, Xiaohua Wu, Jian Zhang, Minal Barve, Nashat Gabrail, David Sommerhalder, KAUSHALENDRA SINGH, Sharon Wilks, Yong Wu, Rujiao Liu, Shuiping Gao, Ziyuan Cao, E. H. M., Caroline Germa, Shima Khodarahmi, M Rezaei Far, Steven Yu, Jenny Yao, Xuelian Zhu	2023	5
5	A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101. Journal of Clinical Oncology ·Yelena Y. Janjigian, Weijing Sun, F. Pacini, Satish Shah, Aaron J. Scott, Dulabh Monga, Madappa N. Kundranda, Joseph S. Tan, Philip J. Gold, Jordan Berlin, Manish R. Patel, Olatunji B. Alese, Erika Hamilton, Michael Cecchini, Brian Andrew Van Tine, Ben George, Rutika Mehta, Rie Shimotakahara, Caroline Germa, Nashat Gabrail	2023	3
6	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial Breast Cancer Research and Treatment ·Gabe S. Sonke, Lowell L. Hart, Mario Campone, Frans Erdkamp, Wolfgang Janni, Sunil Verma, Cristian Villanueva, Erik Jakobsen, Emilio Alba, Erik Wist, Anne Favret, Thomas Bachelot, Roberto Hegg, Paul Wheatley‐Price, Farida Souami, Santosh Sutradhar, Michelle C. Miller, Caroline Germa, Howard A. Burris	2017	61
7	Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib Annals of Oncology ·Caroline Germa, Michelle C. Miller, Pabak Mukhopadhyay, Becker Hewes, Giordano Caponigro, Stefan Scherer, Samit Hirawat	2017	6
8	EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC) Annals of Oncology ·M. Martín Jiménez, Thomas Bachelot, Carlos H. Barrios, Kimberly Blackwell, Stephen Chia, Michelino De Laurentiis, Sara A. Hurvitz, Wolfgang Janni, Bella Kaufman, Sherene Loi, Peter Schmid, DJ Slamon, Katharine Hazell, S. Mondal, Mark Shilkrut, Caroline Germa, Gabriel N. Hortobágyi	2017	4
9	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial Breast Cancer Research and Treatment ·Joyce O’Shaughnessy, Katarína Petráková, Gabe S. Sonke, Pierfranco Conté, Carlos L. Arteaga, David Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, J. Thaddeus Beck, Deborah Lindquist, Farida Souami, S. Mondal, Caroline Germa, Gabriel N. Hortobágyi	2017	87
10	First-line ribociclib + letrozole in HR+, HER2– ABC: Efficacy by baseline tumor markers Annals of Oncology ·Mario Campone, Norbert Marschner, Cristian Villanueva, Gabe S. Sonke, Emilio Alba, Erik Jakobsen, Fei Su, Wei He, Caroline Germa, Fabrice André	2017	2
11	A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) Annals of Oncology ·Fabrice André, Bella Kaufman, Dejan Juric, Eva Ciruelos, Hiroji Iwata, Ingrid A. Mayer, Pierfranco Conté, Hope S. Rugo, Sibylle Loibl, Gábor Rubovszky, Hans Tesch, Kenichi Inoue, Yen‐Shen Lu, L Ryvo, Raj Kathakapa, David Mills, C. Wilke, Caroline Germa, Mario Campone	2016	2
12	PI3K inhibitors as new cancer therapeutics: implications for clinical trial design OncoTargets and Therapy ·Cristian Massacesi, Emmanuelle di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath, Samit Hirawat	2016	195
13	breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) Annals of Oncology ·G. N. Hortobagyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, Pierfranco Conté, Carlos L. Arteaga, David Cameron, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Joyce O’Shaughnessy	2016	6
14	116TiP MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR +, HER2– advanced breast cancer (aBC) Annals of Oncology ·Seock‐Ah Im, Louis WC Chow, Zhi‐Ming Shao, Debu Tripathy, Aditya Bardia, SA Hurvitz, Nadia Harbeck, Marco Colleoni, 柴经国, Caroline Germa, Gareth Hughes, Lee Anne McLean, Selma, Amanda Mueller	2015	1
15	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Journal of Clinical Oncology ·Cristina Saura, José Á. García-Sáenz, Binghe Xu, Wael A. Harb, Rebecca Moroose, Timothy Pluard, Javier Cortés, Paarth J. Raj, Caroline Germa, Kongming Wang, Miguel Martín, José Baselga, Sung‐Bae Kim	2014	103
16	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer European Journal of Cancer ·Miguel Martín, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, István Láng, Sung‐Bae Kim, Caroline Germa, Jennifer Vermette, Н.В. Мартинович, Kongming Wang, Ahmad Awada	2013	119
17	Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer. Cancer Research ·Ahmad Awada, Luc Dirix, J. Thaddeus Beck, Filipa D. Carvalho, Véronique Dièras, Antonio Llombart‐Cussac, Luís Manso, Steven Limentani, Florence Binlich, Caroline Germa, 〔ヒカル〕松宮, Fériel Mouria-Beji, Ceri Powell, Dawn L. Hershman	2009	10
18	Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: A multicenter phase II study Lung Cancer ·David Alvestegui, Jean-Luc Breton, David Braun, Élisabeth Quoix, B. Milleron, D. Debieuvre, P. Jacoulet, Caroline Germa, L. Kayitalire, A Depierre	2006	4
19	First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule Lung Cancer ·Élisabeth Quoix, Jean-Luc Breton, A Ducoloné, B. Mennecier, A Depierre, Étienne Lemarié, Denis Moro‐Sibilot, Caroline Germa, Anne Grete Tandberg	2004	15
20	Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma Annals of Oncology ·Éric Raymond, Michel Fabbro, Valérie Boige, Olivier Rixe, Marc Frénay, Gilles Vassal, Sandrine Faivre, Lim Centley, Caroline Germa, 潤平小林, Laurent Vernillet, Jean‐Pierre Armand	2003	67

About Caroline Germa

Caroline Germa is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Genetics, Biotechnology and Neurology, having authored 54 papers that have together received 1.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (29 papers), Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (16 papers), Colorectal Cancer Treatments and Studies (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Neuroendocrine Tumor Research Advances (5 papers), Lung Cancer Research Studies (5 papers) and Cancer Research and Treatments (4 papers). The work is most often cited by research in Oncology (745 citations), Genetics (238 citations), Pulmonary and Respiratory Medicine (566 citations), Cancer Research (217 citations) and Molecular Biology (364 citations). Caroline Germa has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Samit Hirawat, Patrick Urban, Cristian Massacesi, Miguel Martín, Emmanuelle di Tomaso, Ranjana Tavorath, Kongming Wang, Nathalie Fretault, Sung‐Bae Kim and Bharani Dharan. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, European Journal of Cancer and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact